PAPER Rahman MS, Harrison E, Biggs H, Seikus C, Elliott P, Breen G, Kingston N, Bradley JR, Hill SM, Tom BD, Chinnery PF
SEARCH RESULTS
331926 RESULTS
AD/PD™ 2025: Advances in Science & Therapy
CONFERENCE 2025-04-01 00:00:00-2025-04-05 00:00:00 Vienna, Austria 01 – 05 April 2025 View Conference Website 0
PAPER Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF
Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
Mov Disord. 2016 Sep;31(9):1422-3. Epub 2016 Jul 19 PubMed: 27431803PAPER Leon N, LaCoursiere R, Yarosh D, Patel RS
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
P T. 2017 Nov;42(11):676-711. PubMed: 29089722Peter OBrien
CARLSBAD, United States
Naveen Singhal
United States
Gregory P Louie
NoneFairfield, United States
Pan Nu Thwe
Tatyana Simuni
Northwestern Chicago, United States
Sunil Nair
University of Madison School of Medicine and Public HealthMadison, United States
Marçal Vilar on APP C-Terminal Fragments Stifle Calcium Flow from ER to Lysosomes
COMMENT In this very interesting paper Bretou et al. described the toxic effect produced by the genetic and pharmacologic inhibition of the γ-secretase complex. The authors described that these treatments increased the levels of APP-CTF inducing a dysfunction of
Lixisenatide
THERAPEUTICS Sanofi Adlyxin Lyxumia Other Other In June 2018, French researchers started a Phase 2 study to evaluate the effect of lixisenatide in people with early Parkinson’s disease. The LixiPark trial enrolled 156 participants, with a target dose of 20 μg daily fo
Jourdan Parent on More Evidence that Locus Coeruleus Demise Precedes Cortical Tangles
COMMENT This study is really exciting because it used longitudinal neuroimaging to understand factors that lead to tau accumulation in the brain and to later cognitive decline. We already knew that structural integrity of the locus coeruleus, a brainstem region o
Executive Director, Alzheimer’s Disease Data Initiative
JOB 2024-05-14 Employer Gates Ventures Contact mmaclean@talentongroup.com Description The goals of the AD Data Initiative are to encourage and enable interoperability across existing platforms; expand and enhance the community of data contributors and users; evaluate
Andreas Jeromin on FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.
COMMENT Laboratory-developed test (LDTS) in the current framework are an important tool to accelerate innovation, in particular in rapidly evolving diagnostic markets such as AD. Understanding risks/benefits, the target, performance in racial populations, and mul